Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.
Tian M, Wei JS, Shivaprasad N, Highfill SL, Gryder BE, Milewski D, Brown GT, Moses L, Song H, Wu JT, Azorsa P, Kumar J, Schneider D, Chou HC, Song YK, Rahmy A, Masih KE, Kim YY, Belyea B, Linardic CM, Dropulic B, Sullivan PM, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL, Orentas RJ, Cheuk AT, Khan J. Tian M, et al. Among authors: sorensen ph. Cell Rep Med. 2023 Oct 17;4(10):101212. doi: 10.1016/j.xcrm.2023.101212. Epub 2023 Sep 28. Cell Rep Med. 2023. PMID: 37774704 Free PMC article.
Human antibodies targeting ENPP1 as candidate therapeutics for cancers.
Chu X, Baek DS, Li W, Shyp T, Mooney B, Hines MG, Morin GB, Sorensen PH, Dimitrov DS. Chu X, et al. Among authors: sorensen ph. Front Immunol. 2023 Jan 25;14:1070492. doi: 10.3389/fimmu.2023.1070492. eCollection 2023. Front Immunol. 2023. PMID: 36761762 Free PMC article.
Engineered CD47 protects T cells for enhanced antitumour immunity.
Yamada-Hunter SA, Theruvath J, McIntosh BJ, Freitas KA, Lin F, Radosevich MT, Leruste A, Dhingra S, Martinez-Velez N, Xu P, Huang J, Delaidelli A, Desai MH, Good Z, Polak R, May A, Labanieh L, Bjelajac J, Murty T, Ehlinger Z, Mount CW, Chen Y, Heitzeneder S, Marjon KD, Banuelos A, Khan O, Wasserman SL, Spiegel JY, Fernandez-Pol S, Kuo CJ, Sorensen PH, Monje M, Majzner RG, Weissman IL, Sahaf B, Sotillo E, Cochran JR, Mackall CL. Yamada-Hunter SA, et al. Among authors: sorensen ph. Nature. 2024 May 15. doi: 10.1038/s41586-024-07443-8. Online ahead of print. Nature. 2024. PMID: 38750365
Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours.
Nabbi A, Beck P, Delaidelli A, Oldridge DA, Sudhaman S, Zhu K, Yang SYC, Mulder DT, Bruce JP, Paulson JN, Raman P, Zhu Y, Resnick AC, Sorensen PH, Sill M, Brabetz S, Lambo S, Malkin D, Johann PD, Kool M, Jones DTW, Pfister SM, Jäger N, Pugh TJ. Nabbi A, et al. Among authors: sorensen ph. Genome Med. 2023 Sep 7;15(1):67. doi: 10.1186/s13073-023-01219-x. Genome Med. 2023. PMID: 37679810 Free PMC article.
Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesicles.
Ruzanov P, Evdokimova V, Pachva MC, Minkovich A, Zhang Z, Langman S, Gassmann H, Thiel U, Orlic-Milacic M, Zaidi SH, Peltekova V, Heisler LE, Sharma M, Cox ME, McKee TD, Zaidi M, Lapouble E, McPherson JD, Delattre O, Radvanyi L, Burdach SE, Stein LD, Sorensen PH. Ruzanov P, et al. Among authors: sorensen ph. J Clin Invest. 2024 Mar 26;134(9):e169470. doi: 10.1172/JCI169470. J Clin Invest. 2024. PMID: 38530366 Free PMC article.
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.
Tian M, Wei JS, Shivaprasad N, Highfill SL, Gryder BE, Milewski D, Brown GT, Moses L, Song H, Wu JT, Azorsa P, Kumar J, Schneider D, Chou HC, Song YK, Rahmy A, Masih KE, Kim YY, Belyea B, Linardic CM, Dropulic B, Sullivan PM, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL, Orentas RJ, Cheuk AT, Khan J. Tian M, et al. Among authors: sorensen ph. Cell Rep Med. 2024 May 21;5(5):101586. doi: 10.1016/j.xcrm.2024.101586. Epub 2024 May 9. Cell Rep Med. 2024. PMID: 38723625 Free article. No abstract available.
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.
Weiner AK, Radaoui AB, Tsang M, Martinez D, Sidoli S, Conkrite KL, Delaidelli A, Modi A, Rokita JL, Patel K, Lane MV, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ. Weiner AK, et al. Among authors: sorensen ph. bioRxiv [Preprint]. 2024 Jan 7:2023.12.06.570390. doi: 10.1101/2023.12.06.570390. bioRxiv. 2024. PMID: 38106022 Free PMC article. Preprint.
233 results